Physician profile
Tilak Baba
NPI 1093058307
$2,925.45
in general payments reported to CMS, 2019-2025
20 companies · $770 in 2025
The $770 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,005 · 2021: $69.66 · 2023: $188 · 2024: $893 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,840 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,840.27 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $739.03 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Gilead Sciences, INC. | $288.38 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $277.91 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Lilly USA, LLC | $227.84 | 2024-2025 | Omvoh |
| Covidien Lp | $190.00 | 2019 | |
| Janssen Biotech, INC. | $173.60 | 2023-2025 | Tremfya, Simponi Aria, Remicade |
| Endogastric Solutions, INC | $152.91 | 2019 | |
| Ardelyx, INC. | $125.76 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $122.33 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $115.22 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.51 | 2024-2025 | Entyvio, Eohilia |
| Janssen Scientific Affairs, LLC | $102.36 | 2019 | |
| Pfizer INC. | $95.92 | 2024-2025 | |
| Ironwood Pharmaceuticals, INC | $44.23 | 2024 | |
| Intercept Pharmaceuticals, INC. | $40.03 | 2024-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $33.50 | 2025 | Voquezna |
| Fresenius Kabi USA, LLC | $33.29 | 2023 | Idacio |
| Aimmune Therapeutics, INC. | $30.90 | 2024 | |
| Alexion Pharmaceuticals, INC. | $18.25 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tilak Baba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.